Literature DB >> 19480960

Treatment of cervical cancer in Italy: strategies and their impact on the women.

Rosa De Vincenzo1, Giulia Amadio, Caterina Ricci, Angelo Licameli, Gabriella Ferrandina, Giovanni Capelli, Giovanni Scambia.   

Abstract

Treatment of cervical cancer greatly varies according to the stage of the disease. Laparoscopic surgical staging is emerging as a valid approach, compared to clinical and imaging staging, to better identify the treatment plan. Minimally invasive surgery plays the greatest role in the treatment of early cervical carcinoma (ECC). Laparoscopically assisted radical vaginal hysterectomy (LARVH) is an alternative surgical strategy in this subset of patients. Interest has been increasing in using conservative fertility-sparing surgery such as laparoscopic vaginal radical trachelectomy (LVRT) or chemo-conization, options to be preferred in selected patients, with early-stage disease and asking for future fertility. Chemoradiotherapy currently represents the gold standard in the treatment of patient with locally advanced cervical cancer (LACC). In Italy, neoadjuvant chemotherapy (NACT) followed by radical surgery is today emerging as a valid alternative to the standard chemoradiation and the paclitaxel, ifosfamide and cisplatin (TIP) regimen is one of the most active neoadjuvant chemotherapeutic treatments. Moreover, the combination of different strategies to maximize local control should be considered. Among different approaches to this issue the use of a three-modality treatment, including radiotherapy, chemotherapy and surgery has been investigated. Our data on a large single-institutional series of LACC patients treated with chemoradiation followed by radical surgery confirm that this three-modality treatment can achieve overall survival (OS) and Disease Free Survival (DFS) rates at least comparable to chemoradiation alone, with an acceptable rate of complications. Tailoring of radical surgery, on the basis of intraoperative findings, such as lympho-nodes status, might play an important role in diminishing the overall rate of complications and eventually improve quality of life (QoL) of these patients. Cervical cancer generally has an aggressive impact on relatively young women and, as we experienced, the relevance of psychosocial aspects in gynaecologic oncology has become a main issue.

Entities:  

Mesh:

Year:  2009        PMID: 19480960     DOI: 10.1016/j.vaccine.2008.11.110

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Neoadjuvant chemotherapy with paclitaxel plus cisplatin before radical surgery for locally advanced cervical cancer during pregnancy: A case series and literature review.

Authors:  Huiqiong Huang; Yi Quan; Xiaorong Qi; Ping Liu
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

2.  Knockdown of PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical adenocarcinoma cells to doxorubicin and paclitaxel.

Authors:  Anthony Stanislaus; Athirah Bakhtiar; Diyana Salleh; Snigdha Tiash; Tahereh Fatemian; Sharif Hossain; Toshihiro Akaike; Ezharul Hoque Chowdhury
Journal:  Cancer Cell Int       Date:  2012-06-18       Impact factor: 5.722

3.  Knowledge, attitude, and experience of cervical cancer and screening among Sub-saharan African female students in a UK University.

Authors:  Faith Sopuruchukwu Ogbonna
Journal:  Ann Afr Med       Date:  2017 Jan-Mar

4.  Efficacy of neoadjuvant platinum-based chemotherapy during the second and third trimester of pregnancy in women with cervical cancer: an updated systematic review and meta-analysis.

Authors:  Yizuo Song; Yi Liu; Min Lin; Bo Sheng; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2018-12-19       Impact factor: 4.162

5.  A Fifteen-Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer.

Authors:  Xun Tian; Xin Wang; Zifeng Cui; Jia Liu; Xiaoyuan Huang; Caixia Shi; Min Zhang; Ting Liu; Xiaofang Du; Rui Li; Lei Huang; Danni Gong; Rui Tian; Chen Cao; Ping Jin; Zhen Zeng; Guangxin Pan; Meng Xia; Hongfeng Zhang; Bo Luo; Yonghui Xie; Xiaoming Li; Tianye Li; Jun Wu; Qinghua Zhang; Gang Chen; Zheng Hu
Journal:  Adv Sci (Weinh)       Date:  2021-03-18       Impact factor: 16.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.